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Background: The erosion of the early mortality advantage of elective endovascular aneurysm repair
(EVAR) compared with open repair of abdominal aortic aneurysm remains without a satisfactory
explanation.
Methods: An individual-patient data meta-analysis of four multicentre randomized trials of EVAR versus
open repair was conducted to a prespecified analysis plan, reporting on mortality, aneurysm-related
mortality and reintervention.
Results: The analysis included 2783 patients, with 14 245 person-years of follow-up (median 5⋅5 years).
Early (0–6 months after randomization) mortality was lower in the EVAR groups (46 of 1393 versus 73 of
1390 deaths; pooled hazard ratio 0⋅61, 95 per cent c.i. 0⋅42 to 0⋅89; P = 0⋅010), primarily because 30-day
operative mortality was lower in the EVAR groups (16 deaths versus 40 for open repair; pooled odds
ratio 0⋅40, 95 per cent c.i. 0⋅22 to 0⋅74). Later (within 3 years) the survival curves converged, remaining
converged to 8 years. Beyond 3 years, aneurysm-related mortality was significantly higher in the EVAR
groups (19 deaths versus 3 for open repair; pooled hazard ratio 5⋅16, 1⋅49 to 17⋅89; P = 0⋅010). Patients
withmoderate renal dysfunction or previous coronary artery disease had no early survival advantage under
EVAR. Those with peripheral artery disease had lower mortality under open repair (39 deaths versus 62
for EVAR; P=0⋅022) in the period from 6 months to 4 years after randomization.
Conclusion: The early survival advantage in the EVAR group, and its subsequent erosion, were con-
firmed. Over 5 years, patients of marginal fitness had no early survival advantage from EVAR com-
pared with open repair. Aneurysm-related mortality and patients with low ankle : brachial pressure
index contributed to the erosion of the early survival advantage for the EVAR group. Trial registra-
tion numbers: EVAR-1, ISRCTN55703451; DREAM(Dutch Randomized Endovascular AneurysmMan-
agement), NCT00421330; ACE (Anévrysme de l’aorte abdominale, Chirurgie versus Endoprothèse),
NCT00224718; OVER (Open Versus Endovascular Repair Trial for Abdominal Aortic Aneurysms),
NCT00094575.
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Introduction
Open repair of abdominal aortic aneurysm (AAA) was
first introduced by Dubost in 19511. In the 1990s, the
less invasive endovascular aneurysm repair (EVAR) was
introduced; EVAR-12, the first multicentre randomized
trial of EVAR versus open repair, was started in 1999 in
the UK. This was soon followed by the DREAM3 and
ACE4 multicentre trials in Europe, and the OVER trial5
in the USA.
Each of the randomized trials of EVAR versus open repair
recruited patients (suitable for either open or endovas-
cular repair) with slightly different entry characteristics
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with respect to age, sex, aneurysm morphology and other
demographics. The EVAR-1, DREAM and OVER trials
all showed an early survival benefit for EVAR, whereas
ACE did not. This early survival benefit for EVAR was
lost within 1–3 years in the EVAR-1 and DREAM trials,
but not until later in the OVER trial3,5,6. This ‘catch-up’
in mortality has been noted in many other studies, includ-
ing a Cochrane review7 and analyses of the Medicare
database8, but no satisfactory explanation for this phe-
nomenon has emerged. The Cochrane review7 was lim-
ited by not being able to report aneurysm-related mortality
or subgroup analyses. Each trial individually has been too
small to investigate the reasons for the catch-up mortality
in the EVAR groups, or to answer themuch discussed ques-
tion of whether younger and fitter patients (or other sub-
groups) should be offered open repair, which is considered
more durable than EVAR9,10. This catch-up in mortality
needs to be avoided if EVAR is to outperform open repair
in the longer term. To try to address some of these issues,
the investigators of the four RCTs agreed to pool their data
for an individual-patient data meta-analysis.
Methods
In July 2013, MEDLINE, Embase and clinical trial
databases were searched for randomized trials comparing
open and endovascular repair of AAAs. The search terms
used were: abdominal aortic aneurysm, AAA, endovascular,
stent, open repair and randomized trial. From 275 reports,
four eligible trials reporting mid-term follow-up were
identified (Appendix S1, supporting information).
The methods for the four multicentre trials included in
this meta-analysis have been published previously6,11–13.
The EVAR-1 trial randomized 1252 patients (90⋅7 per cent
men), with aneurysm diameter more than 5⋅5 cm, between
September 1999 and August 2004 in theUK.TheDREAM
trial randomized 351 patients (91⋅7 per cent men), with
aneurysm diameter at least 5 cm, between November 2000
and December 2003 in the Netherlands and Belgium. The
OVER trial randomized 881 patients (99⋅4 per cent men),
with aneurysm diameter 5⋅0 cm or larger, between Octo-
ber 2002 and April 2008 at Veterans Affairs hospitals in
the USA. The ACE trial randomized 306 patients (99⋅0
per cent men), with aneurysm diameter exceeding 5⋅0 cm,
between March 2003 and March 2008 in France; seven
patients withdrew consent before discharge from hospi-
tal. All patients were considered fit for open surgery under
general anaesthesia and all trials used approved devices for
EVAR, predominantly within the manufacturers’ instruc-
tions for use, and followed up patients for a minimum
of 3 years.
The four data sets were merged based on fields available
in the case record forms of the largest trial (EVAR-1); range
checks were conducted and queries resolved with the indi-
vidual trial coordinating centres. The common baseline
variables across the trials were: age, sex, history of smok-
ing, diabetes, coronary artery disease (defined as previous
stable or unstable angina or myocardial infarction), BMI,
maximum aneurysm diameter, proximal aortic neck length
and diameter, ankle : brachial pressure index (ABPI) and
creatinine concentration, used for calculation of estimated
glomerular filtration rate (eGFR)14 but without informa-
tion on ethnicity. Each trial also contained some data on
hypertension, which was included in a modified Wilkins
cardiovascular survival risk score15 (Table S1, supporting
information). The reporting of both drug use (including
antiplatelet and lipid-lowering agents) and reinterventions
was very different in the four trials (particularly intestinal
and wound-related reinterventions following open repair).
The postoperative surveillance protocol was identical for
both randomized groups in all trials, except for DREAM
where, after 2 years, surveillance was relaxed for the open
repair group. However, for complications, only endoleaks
after EVAR were reported similarly across the trials;
laparotomy-related complications were not.
Statistical analysis
The primary analyses considered the groups as random-
ized within each trial. Mortality after randomization was
assessed at both 30 days, in hospital and then in three
defined intervals: 0–6months, 6months to 4 years and
more than 4 years after randomization. Aneurysm-related
mortality included: death from primary aneurysm rupture;
within 30 days of aneurysm repair or any reinterven-
tion; and rupture after repair. Given the different times
between randomization and aneurysm repair in the four
trials, aneurysm-related mortality also was assessed at
30 days, 31 days to 3 years and more than 3 years after
aneurysm repair. Kaplan–Meier survival curves by ran-
domized group were generated from the combined data
from all four trials, and the restricted mean life-years
up to a certain time estimated by the area under the
curve up to that time16. Logistic regression was used
to compare operative (30-day) and in-hospital mortal-
ity among patients who underwent aneurysm repair, and
Cox proportional hazards regression to compare total
and aneurysm-related mortality and time to reinterven-
tion. A two-stage individual-patient data meta-analysis
was performed. First analyses were conducted separately
within each trial and then pooled time period-specific esti-
mates were calculated using random-effects meta-analysis,
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Table 1 Baseline and postrandomization characteristics of patients in the four trials
EVAR-1 DREAM OVER ACE
(n =1252) (n=351) (n=881) (n= 299)
Baseline variables
Age (years)* 74(6) 70(7) 70(8) 69(7)
Men 1135 (90⋅7) 322 (91⋅7) 876 (99⋅4) 296 (99⋅0)
BMI (kg/m2)* 26⋅5(4⋅5) 26⋅7(4⋅7) 28⋅6(5⋅4) 27⋅2(3⋅5)
Smoking status§
Current smoker 270 (21⋅6) 130 (37⋅0) 363 (41⋅2) 72 (24⋅1)
Ex-smoker 863 (68⋅9) 78 (22⋅2) 481 (54⋅6) 75 (25⋅1)
Diabetes 128 (10⋅2) 35 (10⋅0) 200 (22⋅7) 49 (16⋅4)
Previous angina/MI 492 (39⋅3) 153 (43⋅6) 268 (30⋅4) 115 (38⋅5)
ABPI*¶ 1⋅0(0⋅2) 1⋅0(0⋅2) 1⋅0(0⋅2) n.a.
Creatinine (μmol/l)† 102 (90–119) 95 (84–109) 97 (80–110) 93 (82–110)
EQ-5D™ score* 0⋅82(0⋅12) 0⋅84(0⋅11) 0⋅85(0⋅09) n.a.
AAA diameter (cm)* 6⋅5(0⋅9) 6⋅0(0⋅9) 5⋅7(0⋅9) 5⋅6(0⋅7)
AAA neck length (cm)* 2⋅8(1⋅2) 2⋅5(1⋅2) 2⋅6(1⋅2) 2⋅8(1⋅0)
AAA neck diameter (cm)* 2⋅35(0⋅30) 2⋅39(0⋅33) 2⋅26(0⋅35) 2⋅36(0⋅33)
Postrandomization parameters
Time from randomization to repair (days)†# 40 (1–576) 39 (3–209) 17 (0–290) 27 (1–203)
Commenced repair in compliance with randomization 1165 (93⋅1) 339 (96⋅6) 853 (96⋅8) 277 (92⋅6)
Follow-up for mortality (years)† 6⋅0 (3⋅9–7⋅3) 6⋅0 (5⋅0–6⋅8) 5⋅4 (4⋅1–6⋅8) 3⋅1 (2⋅1–3⋅4)
30-day operative mortality
EVAR 11 of 614 (1⋅8) 2 of 170 (1⋅2) 1 of 439 (0⋅2) 2 of 150 (1⋅3)
Open repair 26 of 602 (4⋅3) 5 of 173 (2⋅9) 8 of 429 (1⋅9) 1 of 147 (0⋅7)
Reintervention rate‡
EVAR 174 of 3381 (5⋅1) 77 of 906 (8⋅5) 155 of 2334 (6⋅6) 32 of 419 (7⋅6)
Open repair 64 of 3309 (1⋅9) 41 of 932 (4⋅4) 104 of 2276 (4⋅6) 10 of 408 (2⋅5)
Values in parentheses are percentages unless indicated otherwise; *values are mean(s.d.), †median (i.q.r.) and ‡rate per 100 person-years. §Ex-smokers in
ACE and DREAM were defined as those smoking in the 10 years before randomization. ¶Mean and median ankle : brachial pressure index (ABPI) were
almost identical. #For those who underwent aneurysm repair. EVAR, endovascular aneurysm repair; MI, myocardial infarction; n.a., not available; EQ,
EuroQol (EuroQoLGroup, Rotterdam, The Netherlands); AAA, abdominal aortic aneurysm. Between-trial differences were observed for all baseline
characteristics (P< 0⋅001, Kruskal–Wallis test for continuous variables, Pearson’s χ2 test for categorical variables). Drug therapy was recorded so
differently for each trial that it is not reported here.
with between-study heterogeneity estimated using the
method of DerSimonian and Laird17. The proportion of
between-trial variability beyond that expected by chance
was quantified using the I2 statistic18. All analyses were then
repeated, adjusting for the following baseline co-variables:
age, sex, maximum aneurysm diameter and log creatinine.
The subgroups age, sex, eGFR, coronary artery disease,
ABPI, modified Wilkins cardiovascular survival risk score,
maximum aneurysm diameter, proximal aneurysm neck
diameter and neck length were assessed for differences in
the effect of the EVAR and open strategies by including an
interaction term between the subgroup and randomized
group in a Cox regression model. All measures except for
sex and coronary artery disease were entered as continuous
variables to assess effect modification. Each inter-
action term was pooled across the trials using random-
effects meta-analysis and its statistical significance assessed
using a Wald test, taking the 5 per cent level as significant.
For presentation purposes only (and not for assessing
significance), hazard ratios are shown by dichotomizing
continuous measures at chosen cut-off points (age 72
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Fig. 1 Kaplan–Meier survival curves for overall total mortality, by
randomized group, for all 2783 patients in the four trials
combined. EVAR, endovascular aneurysm repair
years, eGFR 68⋅4ml per min per 1⋅73m2, ABPI 0⋅9,
cardiovascular risk score 2 major risk factors, maximum
AAA diameter 5⋅9 cm, neck diameter 2⋅3 cm, neck length
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Table 2 Unadjusted and adjusted hazard ratios for total mortality by time since randomization
EVAR-1 DREAM OVER ACE Pooled
(n=1252) (n=351) (n=881) (n=299) (n=2783)
Proportion of patients who died*
All patients
EVAR 260 of 626 (7⋅5) 58 of 173 (6⋅2) 146 of 444 (6⋅3) 17 of 150 (4⋅1) 481 of 1393 (6⋅7)
Open repair 264 of 626 (7⋅7) 60 of 178 (6⋅2) 146 of 437 (6⋅4) 12 of 149 (2⋅9) 482 of 1390 (6⋅8)
Time since randomization
0–6 months
EVAR 26 of 626 (8⋅5) 6 of 173 (7⋅1) 11 of 444 (5⋅0) 3 of 150 (4⋅6) 46 of 1393 (6⋅7)
Open repair 45 of 626 (15⋅0) 10 of 178 (11⋅6) 17 of 437 (8⋅0) 1 of 149 (1⋅4) 73 of 1390 (10⋅9)
6months to 4 years
EVAR 125 of 599 (6⋅7) 33 of 167 (6⋅2) 73 of 433 (5⋅2) 13 of 146 (3⋅8) 244 of 1345 (5⋅9)
Open repair 116 of 581 (6⋅3) 25 of 168 (4⋅6) 78 of 420 (5⋅9) 10 of 146 (3⋅0) 229 of 1315 (5⋅7)
>4 years
EVAR 109 of 472 (8⋅4) 19 of 134 (6⋅0) 62 of 348 (8⋅6) 1 of 33 (17⋅7) 191 of 987 (8⋅2)
Open repair 103 of 461 (7⋅9) 25 of 143 (7⋅4) 51 of 331 (7⋅0) 1 of 23 (17⋅5) 180 of 958 (7⋅6)
Unadjusted hazard ratio†
All patients 0⋅98 1⋅00 0⋅97 1⋅52 0⋅99
(0⋅82, 1⋅16) (0⋅70, 1⋅44) (0⋅77, 1⋅23) (0⋅71, 3⋅25) (0⋅87, 1⋅13)
Time since randomization
0–6 months 0⋅57 0⋅60 0⋅63 2⋅97 0⋅61
(0⋅35, 0⋅92) (0⋅22, 1⋅66) (0⋅29, 1⋅34) (0⋅31, 28⋅60) (0⋅42, 0⋅89)¶
6months to 4 years 1⋅06 1⋅36 0⋅89 1⋅25 1⋅04
(0⋅82, 1⋅37) (0⋅81, 2⋅28) (0⋅65, 1⋅23) (0⋅55, 2⋅86) (0⋅87, 1⋅25)
>4 years 1⋅06 0⋅81 1⋅22 – 1⋅07
(0⋅81, 1⋅39) (0⋅45, 1⋅47) (0⋅85, 1⋅77) (0⋅88, 1⋅32)
No. of patients in adjusted analysis 1246 339 881 281 2747
Adjusted hazard ratio†‡
All patients 1⋅00 0⋅88 1⋅04 1⋅43 1⋅01
(0⋅84, 1⋅19) (0⋅61, 1⋅27) (0⋅82, 1⋅31) (0⋅63, 3⋅22) (0⋅89, 1⋅14)
Time since randomization
0–6 months 0⋅58 0⋅42 0⋅62 –§ 0⋅57
(0⋅36, 0⋅95) (0⋅14, 1⋅25) (0⋅29, 1⋅33) (0⋅39, 0⋅84)¶
6months to 4 years 1⋅08 1⋅15 0⋅94 1⋅14 1⋅05
(0⋅84, 1⋅40) (0⋅68, 1⋅95) (0⋅69, 1⋅30) (0⋅49, 2⋅68) (0⋅87, 1⋅26)
>4 years 1⋅11 0⋅79 1⋅30 –§ 1⋅12
(0⋅85, 1⋅46) (0⋅43, 1⋅44) (0⋅89, 1⋅90) (0⋅91, 1⋅38)
Value in parentheses are *rate per 100 person-years and †95 per cent confidence intervals. ‡Adjusted for age, sex, maximum aneurysm diameter and log
creatinine. §Too few events to estimate a hazard ratio. EVAR, endovascular aneurysm repair. ¶P< 0⋅050.
2⋅5 cm), estimating the hazard ratios within each subgroup
and pooling these across studies.
The hazard of reintervention following aneurysm repair
was analysed using a multiple failure time model (Appendix
S1, supporting information). In addition, for patients who
received EVAR, mortality hazard ratios were investigated
in individuals with and without a detected/treated type II
endoleak (Appendix S1, supporting information).
All analyses were performed using Stata® version 13
(StataCorp, College Station, Texas, USA).
Results
A total of 2783 patients, with 14 245 person-years of
follow-up, were included in this meta-analysis. Baseline
characteristics are shown in Table 1; there were signifi-
cant intertrial differences for all variables. Patients in the
EVAR-1 trial were older and had larger aneurysms than
patients in the other trials. Nearly all patients in the OVER
and EVAR-1 trials had a history of smoking, compared
with about half of those in the DREAM and ACE trials.
Patients in the OVER trial had the highest BMI and this
trial had the highest proportion of patients with diabetes.
Postrandomization characteristics of the trials are also are
summarized in Table 1. The median follow-up was 6⋅0, 6⋅0,
5⋅4 and 3⋅1 years for EVAR-1, DREAM, OVER and ACE
respectively, and 5⋅5 years for the pooled data. Compliance
with randomized allocation was at least 92 per cent.
Total mortality
Over the follow-up of all four trials there were 481 deaths
in the EVAR groups and 482 in the open repair groups.
Kaplan–Meier curves by randomized group for total
mortality across all four trials are shown in Fig. 1. Overall,
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Fig. 2 Unadjusted hazard ratios, with 95 per cent confidence intervals, for total mortality overall and at 0–6 months, 6 months to 4 years
and more than 4 years since randomization. EVAR, endovascular aneurysm repair
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Fig. 3 Odds ratios, with 95 per cent confidence intervals, for mortality within 30 days of operation. EVAR, endovascular aneurysm repair
there was no difference in total mortality over the
follow-up period of the trials (hazard ratio 0⋅99, 95
per cent c.i. 0⋅87 to 1⋅13) (Table 2, Fig. 2). Between 0 and 6
months, mortality was lower for the EVAR groups, with 46
deaths versus 73 for open repair (hazard ratio 0⋅61, 0⋅42 to
0⋅89) and no evidence of heterogeneity between the trials.
The early survival advantage of EVAR in the first 6 months
was largely attributable to the lower 30-day operative
mortality for EVAR versus open repair groups (unadjusted
pooled odds ratio 0⋅40, 95 per cent c.i. 0⋅22 to 0⋅74)
(Fig. 3). After this, the early advantage for the EVAR group
was lost and the hazard ratios moved (non-significantly) in
© 2017 The Authors. BJS published by John Wiley & Sons Ltd www.bjs.co.uk BJS 2017; 104: 166–178
on behalf of BJS Society Ltd.
Outcomes of endovascular or open repair for abdominal aortic aneurysm over 5 years 171
Table 3 Unadjusted and adjusted hazard ratios for aneurysm-related mortality by time since operation for those who underwent surgery
EVAR-1 DREAM OVER ACE Pooled
(n=1216) (n=343) (n=868) (n=297) (n=2724)
Proportion of patients who died*
All patients
EVAR 31 of 614 (0⋅9) 6 of 170 (0⋅7) 9 of 439 (0⋅4) 7 of 150 (1⋅7) 53 of 1373 (0⋅8)
Open repair 32 of 602 (1⋅0) 10 of 173 (1⋅1) 13 of 429 (0⋅6) 1 of 147 (0⋅3) 56 of 1351 (0⋅8)
Time since operation
0–30 days
EVAR 11 of 614 (22⋅0) 2 of 170 (14⋅3) 1 of 439 (2⋅8) 2 of 150 (16⋅4) 16 of 1373 (14⋅2)
Open repair 26 of 602 (53⋅7) 5 of 173 (35⋅5) 8 of 429 (22⋅9) 1 of 147 (8⋅3) 40 of 1351 (36⋅5)
31days to 3 years
EVAR 7 of 603 (0⋅4) 2 of 168 (0⋅4) 5 of 438 (0⋅4) 4 of 148 (1⋅1) 18 of 1357 (0⋅5)
Open repair 4 of 576 (0⋅3) 5 of 168 (1⋅1) 4 of 421 (0⋅3) 0 of 146 (0) 13 of 1311 (0⋅4)
>3 years
EVAR 13 of 498 (0⋅8) 2 of 140 (0⋅5) 3 of 380 (0⋅3) 1 of 78 (2⋅3) 19 of 1096 (0⋅6)
Open repair 2 of 484 (0⋅1) 0 of 146 (0) 1 of 352 (0⋅1) 0 of 72 (0) 3 of 1054 (0⋅1)
Unadjusted hazard ratio*
All patients 0⋅94 0⋅61 0⋅68 6⋅86 0⋅89
(0⋅57, 1⋅54) (0⋅22, 1⋅68) (0⋅29, 1⋅59) (0⋅84, 55⋅78) (0⋅51, 1⋅56)
Time since operation
0–30 days 0⋅41 0⋅40 0⋅12 1⋅97 0⋅41
(0⋅20, 0⋅83) (0⋅08, 2⋅08) (0⋅02, 0⋅97) (0⋅18, 21⋅76) (0⋅22, 0⋅74)¶
31days to 3 years 1⋅69 0⋅40 1⋅20 –§ 1⋅07
(0⋅50, 5⋅77) (0⋅08, 2⋅08) (0⋅32, 4⋅47) (0⋅49, 2⋅36)
>3 years 6⋅35 – 3⋅18 –§ 5⋅16
(1⋅43, 28⋅15) (0⋅33, 30⋅64) (1⋅49, 17⋅89)¶
No. of patients in adjusted analysis 1211 331 868 280 2690
Adjusted hazard ratio†‡
All patients 0⋅97 0⋅44 0⋅71 –§ 0⋅81
(0⋅59, 1⋅59) (0⋅15, 1⋅30) (0⋅30, 1⋅67) (0⋅55, 1⋅21)
Time since operation
0–30 days 0⋅42 0⋅21 0⋅13 –§ 0⋅36
(0⋅21, 0⋅86) (0⋅02, 1⋅85) (0⋅02, 1⋅05) (0⋅19, 0⋅67)¶
31days to 3 years 1⋅82 0⋅32 1⋅13 –§ 0⋅98
(0⋅52, 6⋅36) (0⋅06, 1⋅65) (0⋅29, 4⋅39) (0⋅38, 2⋅55)
>3 years 6⋅58 – 3⋅19 –§ 5⋅30
(1⋅48, 29⋅21) (0⋅33, 31⋅26) (1⋅52, 18⋅46)¶
Value in parentheses are *rate per 100 person-years and †95 per cent confidence intervals. ‡Adjusted for age, sex, maximum aneurysm diameter and log
creatinine. §Too few events to estimate a hazard ratio. EVAR, endovascular aneurysm repair. ¶P< 0⋅050.
the direction of open repair. Adjusted hazard ratios were
similar. By 5 years, the estimated survival rate was 73⋅6
(95 per cent c.i. 71⋅1 to 75⋅9) per cent in both the EVAR
and open repair groups, with an expected 0⋅06 additional
life-years in the EVAR group, corresponding to 23 (95
per cent c.i. –16 to 61) days (P= 0⋅246). The causes of
death by time period are shown in Table S2 (supporting
information).
Aneurysm-related mortality
The findings for aneurysm-related mortality were similar
in direction, with relative benefit for the EVAR groups 0–6
months after randomization (25 in EVAR groups versus 55
in open repair groups; pooled unadjusted hazard ratio 0⋅44,
95 per cent c.i. 0⋅26 to 0⋅76). In later time periods, the
results moved in the direction of open repair: the pooled
hazard ratio was 1⋅43 (95 per cent c.i. 0⋅61 to 3⋅34) for 6
months to 4 years and 2⋅29 (0⋅49 to 10⋅85) for over 4 years
(Fig. S1, supporting information). For those who received
aneurysm repair, analysis by time from repair showed a
strong relative advantage for the EVAR group in the first 30
days; between 30 days and 3 years there was no difference
between the groups, but after 3 years there was a significant
relative advantage for the open repair group, with three
aneurysm-related deaths versus 19 in the EVAR groups
(hazard ratio 5⋅16, 1⋅49 to 17⋅89; P= 0⋅010) (Table 3).
Total mortality by subgroups
There was no significant effect of age or sex on the
relative effectiveness of EVAR in preventing deaths
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Age (years)
Sex
eGFR (ml per min per 1·73 m2)
0·149
0·413
0·176
0·386
0·233
0·777
0·150
0·319
0·164
0·024
0·838
0·377
35·2
0·0
0·0
75·3
0·0
0·0
38·1
8·3
64·5
78·3
0·83 (0·66, 1·04)
1·08 (0·92, 1·25)
0·55 (0·24, 1·27)
0·63 (0·41, 0·97)
0·84 (0·61, 1·15)
1·15 (0·92, 1·44)
0·91 (0·63, 1·31)
1·24 (0·78, 1·96)
1·37 (0·82, 2·28)
0·96 (0·85, 1·10)
0·45 (0·08, 2·46)
0·62 (0·42, 0·91)
1·90 (0·81, 4·45)
1·00 (0·83, 1·21)
1·53 (0·73, 3·19)
1·05 (0·85, 1·30)
1·05 (0·89, 1·24)
0·90 (0·74, 1·10)
0·68 (0·43, 1·08)
0·42 (0·21, 0·84)
1·07 (0·84, 1·36)
0·99 (0·72, 1·34)
1·19 (0·90, 1·57)
0·92 (0·55, 1·55)
4
4
2
4
4
4
3
3
2
4
1
4
1
4
2
3
4
4
3
4
4
4
3
3
1333
1450
< 72
≥ 72
< 72
≥ 72
< 72
≥ 72
< 72
≥ 72
< 68·4
≥ 68·4
< 68·4
≥ 68·4
< 68·4
≥ 68·4
< 68·4
≥ 68·4
F
M
F
M
F
M
F
M
962
1450
1304
1356
967
922
146
2629
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2629
111
2512
114
1773
1379
1379
1263
1379
1299
1338
918
958
Characteristic Time interval
All patients
0–6 months
6 months to 4 years
> 4 years
All patients
0–6 months
6 months to 4 years
> 4 years
All patients
0–6 months
6 months to 4 years
> 4 years
Hazard ratio
No. of
trials
No. of
patients Hazard ratio
Interaction
P
I2
(%)
0·25
Favours EVAR Favours open repair
0·5 1 2 4
Fig. 4 Unadjusted hazard ratios, with 95 per cent confidence intervals, for total mortality by subgroups of age, sex and estimated
glomerular filtration rate (eGFR), overall and at 0–6 months, 6 months to 4 years and more than 4 years since randomization.
Interaction P values for age and eGFR were calculated using continuous measures (median eGFR 68⋅4ml per min per 1⋅73m2). Not all
trials contributed to the subgroup analyses or every time point. Hazard ratios for sex could not be estimated in the OVER and ACE
trials owing to small numbers of women. EVAR, endovascular aneurysm repair
in any time period, including the first 6months after
randomization (Fig. 4). There were two subgroups
of patients who appeared to have no early benefit (to
6months) under EVAR versus open repair: patients with
moderate renal dysfunction and those with coronary artery
disease. For those with above-median eGFR, the pooled
hazard ratio of 0⋅42 (95 per cent c.i. 0⋅21 to 0⋅84) was
significantly in favour of EVAR, compared with the less
favourable and non-significant pooled hazard ratio of
0⋅68 (0⋅43 to 1⋅08) for those with worse renal function;
therefore, the interaction between eGFR measure and
treatment group was significant (interaction P= 0⋅024)
(Fig. 4). Similarly, patients with coronary artery disease
gained no early advantage of being in the EVAR group, in
comparison with patients without previous coronary artery
disease (interaction P= 0⋅047) (Fig. 5). None of the mor-
phological aneurysm characteristics, smoking, diabetes
or BMI was associated with mortality (Figs S2 and S3,
supporting information).
Baseline ABPI was not available for the ACE trial. In
the other trials, patients with peripheral artery disease
(ABPI below 0⋅9) had a similar early survival advantage
from being in the EVAR group as those with a higher
ABPI (0⋅9 or above). However, in the 6-month to 4-year
time interval, among those with an ABPI lower than 0⋅9,
the open repair group had a survival advantage (39 deaths
versus 62 in EVAR group; hazard ratio 1⋅67, 1⋅12 to 2⋅49),
in comparison with patients with an ABPI of at least
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Favours EVAR Favours open repair
Angina/MI 0·181 23·9
0·93 (0·79, 1·09)
0·12 (0·91, 1·37)
4
4
1756
1027
3
4
1571
1027
4
4
1682
978
3
3
1207
682
3
3
468
1848
3
3
468
1848
3
3
431
1776
3
3
326
1441
4
4
2089
690
3
4
1885
690
4
4
2007
650
3
3
1459
427
0·047 0·0
0·43 (0·26, 0·72)
1·01 (0·57, 1·78)
0·343 19·1
0·97 (0·77, 1·22)
1·24 (0·85, 1·82)
0·910 0·0
1·10 (0·84, 1·43)
1·05 (0·76, 1·46)
0·382 15·5
1·17 (0·89, 1·54)
0·93 (0·80, 1·08)
0·143 0·0
0·55 (0·28, 1·08)
0·66 (0·41, 1·06)
0·022 0·0
1·67 (1·12, 2·49)
0·90 (0·66, 1·22)
0·715 29·6
1·05 (0·65, 1·68)
1·08 (0·85, 1·37)
0·588 53·5
0·97 (0·77, 1·22)
1·09 (0·86, 1·40)
0·631 0·0
0·50 (0·31, 0·80)
0·86 (0·46, 1·61)
0·988 37·6
1·09 (0·78, 1·53)
1·04 (0·70, 1·55)
0·192 0·0
1·01 (0·80, 1·27)
1·30 (0·84, 2·00)
No
Yes
No
Yes
No
Yes
No
Yes
Characteristic Time interval
All patients
Hazard ratio
No. of
trials
No. of
patients Hazard ratio
Interaction
P
I2
(%)
0·25 0·5 1 2 4
0–6 months
6 months to 4 years
> 4 years
All patientsABPI
0–6 months
6 months to 4 years
> 4 years
All patientsCardiovascular risk score (majors)
0–6 months
6 months to 4 years
> 4 years
< 0·9
≥ 0·9
< 0·9
≥ 0·9
< 0·9
≥ 0·9
< 0·9
≥ 0·9
< 2
≥ 2
< 2
≥ 2
< 2
≥ 2
< 2
≥ 2
Fig. 5 Unadjusted hazard ratios, with 95 per cent confidence intervals, for total mortality by subgroups of history of angina or
myocardial infarction (MI), ankle : brachial pressure index (ABPI) and cardiovascular risk score, overall and at 0–6 months, 6 months to
4 years and more than 4 years since randomization. Interaction P values for ABPI and cardiovascular risk score were calculated using
continuous measures. Not all trials contributed to the subgroup analyses or every time point. The ACE trial did not report ABPI so is
not included in these results. EVAR, endovascular aneurysm repair
0⋅9 (interaction P= 0⋅022). During this interval, in those
with an ABPI lower than 0⋅9, total mortality rates were
9⋅6 and 5⋅7 per 100 person-years in the EVAR and open
repair groups respectively, compared with 5⋅1 and 5⋅8 per
100 person-years respectively in the group with a higher
ABPI. The cause of death in the two ABPI groups by
time period is shown in Table S3 (supporting information).
Analysis of the operative mortality by subgroup showed
that patients with a low ABPI had the highest mortality
rate (Table S4, supporting information), and this group had
higher aneurysm-related mortality throughout. Finally,
a cardiovascular risk score was not discriminatory in any
time period.
Complications and reinterventions
Complications (apart from endoleaks after EVAR) and
reinterventions were reported heterogeneously across the
four trials. The overall rates of reintervention reported
were higher in the EVAR group than in the open repair
group for all trials (Table 1). The risk of reintervention
by time period following aneurysm repair is shown in
Fig. S4 (supporting information); there was substantial
heterogeneity between trials for reinterventions recorded
between 31 days and 3 years.
There was no indication that complications following
EVAR decreased with the year in which the trial com-
menced: these rates, together with types and numbers
of complications, are reported in Table S5 (supporting
information). The commonest reported complication after
EVARwas type II endoleak, which overall was reported 435
times in 325 of 2783 patients (11⋅7 per cent). Corrective
reintervention was performed in 99 of 435 detected type
II endoleaks (22⋅8 per cent). There was no evidence that a
detected type II endoleak (either treated or untreated) was
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associated with worse overall survival (Table S6, supporting
information). The second most common type of compli-
cation was type I endoleak, for which 79 of 120 (65⋅8 per
cent) received an early reintervention. Similarly, early cor-
rection of other serious EVAR-related complications was
attempted in less than two-thirds of patients. Secondary sac
rupture was reported in 37 patients: 33 in the EVAR ran-
domized groups (2⋅4 per cent of patients) and four in the
open groups (0⋅3 per cent), although all four of the latter
patients were treated with EVAR. For those with secondary
rupture following treatment with EVAR, the median time
to rupture was 3⋅5 years (Fig. S5, supporting information).
Of these patients, 11 had a type I endoleak, of which seven
were treated, seven had a type II endoleak, of which three
were treated, two had a type III endoleak, of which one
was treated, and nine had known graft migration. Nine-
teen patients had no endoleaks detected before secondary
sac rupture and one further patient had a thoracic endo-
graft for proximal aortic dissection 3 days earlier. Themean
time between detection of the first endoleak and rupture
was 1⋅8 years. The 30-day mortality rate following rupture
was 62 per cent (23 of 37).
Discussion
These four randomized trials, in Europe and the USA,
provide the best evidence for the early survival advantage
offered by EVAR rather than open repair. Patients prefer
EVAR, the less invasive method of AAA repair, which has
been adopted widely, and the majority of elective repairs
are now performed using EVAR8,19,20. This meta-analysis,
over a 5-year time horizon, confirms that, overall, there is
an early survival advantage for EVAR, which is lost within
3 years of randomization, so that the life-years saved from
EVAR over 5 years are minimal. Between 0 and 6months
after randomization, total and aneurysm-related mortality
rates were lower for the EVAR group, mainly because of
the 2⋅5-fold lower 30-day operative mortality in this group.
However, after this interval, the early EVAR group advan-
tage was eroded progressively. By 3 years after aneurysm
repair, aneurysm-related mortality was five times higher
in the EVAR group (mainly due to secondary rupture or
reinterventions) and this is likely to have contributed to
the ‘catch-up’ in mortality.
Further investigations focused on whether the early sur-
vival advantage was either maintained or lost in subgroups
of patients categorized by preoperative characteristics.
Over a 5-year time horizon, there was no convincing
evidence that being randomized to EVAR or open repair
resulted in differential survival between any subgroups
of the population. This does not support the suggestion
that younger and fitter patients with aortic morphology
suitable for EVAR are likely to benefit from open repair
over 5 years9. However, differential effect modification was
suggested in some subgroups (renal dysfunction, coronary
artery disease) in the first 6months and for those with
peripheral artery disease in the later 6-month to 4-year
time interval, possibly owing to frailty effects.
Low ABPI was introduced as a measure of periph-
eral atherosclerosis21 and is a marker of generalized
atherosclerosis22. This subgroup had the highest pooled
operative mortality, although the relative early advantage
of EVAR was maintained. However, between 6months and
4 years, fortunes reversed in favour of a survival advantage
for the open repair group, a pattern that indicates those
with a low ABPI are another contributor to the ‘catch-up’
in mortality.
All trials enrolled patients with evidence of moderate
renal dysfunction, with 35 per cent of the overall enrolment
having an eGFR below 60ml per min per 1⋅73m2 (chronic
kidney disease stage 3 or above). For these patients, there
was no evidence of a benefit from being randomized to
EVAR (versus open repair), even in the first 6months.
These data are in agreement with an earlier observational
study23 showing a high early postoperative event rate for
patients with low eGFR. Whether renal function deteri-
orates more rapidly after either elective EVAR or open
repair of an AAA has been debated fiercely, and less atten-
tion has been focused on improving perioperative care24.
Similarly, patients with known coronary artery disease had
no evidence of an early survival advantage from being ran-
domized to EVAR. Given that EVAR is less invasive than
open repair, these findings for patients with moderate renal
dysfunction and coronary artery disease are surprising.
Perhaps the stress of EVAR in these subgroups has been
underestimated. It also is possible that those randomized
to EVAR received less stringent preoperative evaluations,
resulting in better perioperative care for the open repair
group with these co-morbidities.
This study has several limitations that restrict its scope.
First, endografts were implanted between 1999 and 2008
using general anaesthesia and today newer endografts
are being used, often with local anaesthesia. Second,
there were different reporting standards across the trials
for baseline characteristics such as smoking and drugs.
Third, the reporting of complications and reinterven-
tions (aneurysm-related and other cardiovascular) was
very heterogeneous across the trials. Fourth, today it is
recognized that type II endoleaks with sac enlargement
can be dangerous25 and that a type II endoleak might even
hide a type I or type III endoleak. Fifth, at the time these
trials recruited (1999–2008), no trial had a clear policy for
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reintervention in the presence of endoleaks after EVAR;
even serious complications such as type I endoleak were
not always corrected quickly, which may have contributed
to the increasing aneurysm-related mortality rate in the
EVAR group at 3 or more years after aneurysm repair.
The reintervention rate was consistently higher in
the EVAR groups (Table 1), although the data are hetero-
geneous and the largest trial did not report incision-related
complications after open repair. It would be reassuring to
learn that by using more recent EVAR devices, according
to the instructions for use, coupled with more rigorous
surveillance, the continuing aneurysm-related mortality
in the EVAR group could be attenuated to minimize the
‘catch-up’ in mortality. To rely entirely on the introduction
of new devices to prevent aneurysm-related mortality in
the EVAR group, especially without adequate surveil-
lance, may be unwise. Recent analyses8 of the Medicare
database support this caution. Correction of the common-
est reported complication of EVAR, type II endoleak, had
no effect on survival.
This meta-analysis confirms the advantage of lower
mortality in the EVAR group in the first 6months and
provides some new insight of how this early advantage of
EVAR is eroded (aneurysm-related mortality and inclu-
sion of those with peripheral artery disease). Addition-
ally, two subgroups of patients were identified who do not
have lower mortality with EVAR at any time, suggesting
that patients with moderate renal dysfunction and those
with established coronary artery disease might benefit from
improved perioperative care, especially for EVAR. Surveil-
lance must focus on reducing aneurysm-related deaths in
the mid and longer term, particularly deaths resulting from
reinterventions and secondary ruptures after EVAR.
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